BELLEVILLE, ON, Aug. 5 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC - News), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its Chief Financial Officer, Patrick Montpetit, is resigning his position effective September 18, 2009 to pursue other career opportunities.
During his nine years with the Company, Patrick has led the Finance and Accounting team through some challenging times and has demonstrated his ability to creatively address those challenges. “Patrick has decided to move on to a new phase in his career and life,” said Graeme McRae, Chairman, President CEO of Bioniche Life Sciences Inc. “We wish him every success in his future endeavours and appreciate his many contributions to Bioniche.”
The search for a new Chief Financial Officer is underway.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 190 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company’s primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2009. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
